

# A systematic review uncovers a wide-gap between COVID-19 in humans and animal models

Salleh N. Ehaideb, Mashan L. Abdullah, Bisher Abuyassin, & Abderrezak Bouchama\*

Experimental Medicine Department, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

## **\*Correspondence**

Dr. Abderrezak Bouchama: [bouchamaab@NGHA.MED.SA](mailto:bouchamaab@NGHA.MED.SA)

(ORCID: 0000-0003-3089-5936)

Experimental Medicine Department, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

## **Abstract**

**Background:** Animal models of COVID-19 have been rapidly reported after the start of the pandemic. We aimed to assess whether the newly created models reproduce the full spectrum of humans COVID-19.

**Methods:** We searched the Medline, as well as BioRxiv and MedRxiv preprint servers for original research published in English from January 1, to May 20, 2020. We used the search terms “COVID-19” OR “SARS-CoV-2” AND, “animal models”, “hamsters”, “nonhuman primates”, “macaques”, “rodent”, “mice”, “rats”, “ferrets”, “rabbits”, “cats”, and “dogs”. Inclusion criteria were the establishment of animal models of COVID-19 as an endpoint. Other inclusion criteria were assessment of prophylaxis, therapies, or vaccines, using animal models of COVID-19.

**Findings:** 13 peer-reviewed studies and 14 preprints met inclusion criteria. The animals used were nonhuman primates (n=13), mice (n=7), ferrets (n=4), hamsters (n=4), and cats (n=1). All animals supported high viral replication in the upper and lower respiratory tract associated with mild clinical manifestations, lung pathology and full recovery. Older animals displayed relatively more severe illness than the younger ones. No animal models developed hypoxemic respiratory failure, multiple organ dysfunction, culminating in death. All species elicited a specific IgG antibodies response to the spike proteins, which were protective against a second exposure. Transient systemic inflammation was observed occasionally in Rhesus macaques, hamsters, and mice. Notably, none of the animals unveiled cytokine storm or coagulopathy.

**Conclusions:** Most of the animal models of COVID-19 recapitulated mild pattern of human COVID-19 with full recovery phenotype. No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.

**Funding:** There was no funding source for this study.

## Introduction

Coronavirus disease 2019 (COVID-19) is a febrile respiratory illness due to a novel viral pathogen severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2)<sup>1,2</sup>. COVID-19 can progress to acute respiratory distress syndrome (ARDS), multiple organ dysfunction/failure (MODS), culminating in death<sup>2-4</sup>.

SARS-CoV-2 is a beta coronavirus that binds with a high affinity to angiotensin-converting enzyme (ACE) 2 receptor and uses the transmembrane serine protease (TMPRSS) 2 as co-receptor to gain entry to cells<sup>5-7</sup>. ACE2 and TMPRSS2 are co-expressed in many tissues and organs, particularly the nasal epithelial cells and alveolar type II cells of the lungs, which may explain in part the easy transmission from person-to-person, and its dissemination within the body in severe and fatal cases<sup>6-13</sup>. Accordingly, SARS-CoV-2-induced COVID-19 has led to a pandemic that overwhelmed the capacity of most national health systems, resulting in a global health crisis<sup>14</sup>. So far, an estimated 11, 280 million persons in 188 countries were infected, of which 531,000 died<sup>15</sup>.

The clinical spectrum of COVID-19 is complex and has been categorized as mild, severe, and critical, representing 81, 14, and 5%<sup>2,3</sup>. The mild pattern comprises patients with either no signs and symptoms or fever and radiological evidence of pneumonia<sup>3</sup>. The severe pattern manifests as rapidly progressive hypoxemic pneumonia involving more than half of the lung with a full recovery phenotype<sup>2,3</sup>. The critical pattern consists of ARDS requiring respiratory assistance, MODS that result in death in approximately half of the patients<sup>2,3,16,17</sup>. Mortality was associated with host factors such as old age, comorbidities, and immune response<sup>4</sup>.

Viral and immunopathological studies revealed distinct patterns between mild and severe or critical forms of COVID-19<sup>4,17-25</sup>. Both severe and critically ill patients displayed higher viral load in the upper respiratory tract than mild cases, together with delayed clearance

overtime<sup>17,18</sup>. Likewise, they presented with lymphopenia due to a decrease in CD4+ and CD8+ T cells, as well as T cells exhaustion accompanied by a marked inflammatory response<sup>20-25</sup>. Pro- and anti-inflammatory cytokines and chemokines concentrations were increased systemically and locally in the lung and correlated with severity<sup>20-22</sup>. In contrast, in the mild illness, the lymphocyte count was normal, with no or minimal inflammatory response<sup>19,22</sup>. Together, these suggest that the viral load and dynamic together with the host inflammatory response may play a pathogenic role.

Clinical and post-mortem studies of fatal cases of COVID-19 demonstrated major alteration of coagulation and fibrinolysis<sup>12,13</sup>. This was associated with widespread thrombosis of small and large vessels, particularly of the pulmonary circulation contributing to death in a third of patients<sup>26-32</sup>. These observations suggest that dysregulated coagulation may be an important mechanism of COVID-19 morbidity and mortality<sup>33</sup>.

In this context, animal models appear crucial to a better understanding of the complex biology of COVID-19. Animal models of SARS-CoV-2-induced COVID-19 have been rapidly reported since the start of the pandemic<sup>34</sup>. However, whether they express the full phenotype of COVID-19, particularly the severe and critical patterns associated with lethality, remains to be determined. In this systematic review, we examined whether the newly created animal models reproduce the phenotype of human COVID-19. Moreover, we examined the knowledge generated by these models of COVID-19 including viral dynamic and transmission, pathogenesis, and testing of therapy and vaccines.

## **Material and methods**

### **Search strategy and selection criteria**

We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement<sup>35</sup> to identify studies describing the creation of an animal model of COVID-19 as an endpoint (Box1 and supplemental Box1 ).

## Results

The systematic search identified 101 studies and 326 preprints, of which 400 articles were excluded because they were reviews, non-original articles, or unrelated to the COVID-19 infection (Fig.1 and supplemental Table 1). 13 peer-reviewed studies and 14 preprints were included in the analysis.

The studies used Old-world nonhuman primates (n=13)<sup>36-48</sup>, mice (n=7)<sup>49-55</sup>, hamsters (n=4)<sup>55-58</sup>, ferrets (n=4)<sup>59-62</sup>, cats, and dogs (n=1)<sup>62</sup> (Tables 1-4). Male and female, as well as young and old, were included but with no associated comorbidities. The aims were to investigate the pathogenesis of COVID-19 (n=15), testing drugs and vaccines (n=14), the host immune response (n=6), and the virus dynamic and transmission (n=4) (Tables 1-4).

Other animals studied included pigs, ducks, and chickens, however none of them supported SARS-CoV-2 replication, and hence will not be discussed further<sup>62,63</sup>.

All the experimental animals were inoculated with SARS-CoV-2 with various strains, doses, and route of administration that differed across studies (Table 1-4). Likewise, the time-point for tissue collection and pathological assessment were variables. These together precluded any comparisons between the animal models either intra-species or inter-species.

### Nonhuman primate models

*Viral model:* Rhesus macaques (n=10)<sup>36-45</sup>, Cynomolgus (n=3)<sup>45-47</sup>, and African Green model (n=1)<sup>48</sup> from the Old World primates and common marmoset (n=1)<sup>45</sup> from the New World were assessed as models for COVID-19 (Table 1). SARS-CoV-2 strains, dose and route of

inoculation were different across studies. Infection through the intragastric, conjunctival and intratracheal routes elicited no lung pathology, mild and severe interstitial pneumonia, respectively, thus, emphasizing the relevance of the entry site of the virus in the expression of the disease<sup>44</sup>. The animals were euthanized at different time-points post- inoculation ranging from 3 to 33 days.

*Phenotype:* The animals displayed variable clinical manifestations from none to fever, altered respiratory patterns, and other general signs (Table 1). The clinical manifestations were not different between old and young macaques<sup>45-47</sup>. Structural and ultrastructural examination of the respiratory tract were also variables including mild to moderate interstitial pneumonitis, edema, foci of diffuse alveolar damage with occasional hyaline membrane formation and pneumocytes type II hyperplasia (Table 1). Old rhesus macaques exhibited more diffuse and severe interstitial pneumonia than young ones<sup>46</sup>. No extrapulmonary injury was documented except in two studies, which revealed inflammatory cells infiltrating the jejunum, and colon, steatosis of the liver, and alteration of myocardial fiber architecture with increased mitochondrial density<sup>32,45</sup>. No mortality was observed in any of the nonhuman primate models.

Comparisons between species of nonhuman primates was not possible except in one study, which suggested that rhesus macaques was superior to cynomolgus and common marmoset as models of human COVID-19<sup>45</sup>. Other comparisons suggested that SARS-CoV elicited more severe lung pathology than SARS-CoV-2 and MERS-CoV<sup>47</sup> (Table 1).

*Viral and host interaction:* The virus replicated rapidly and at higher titers in upper airway and lung and intrathoracic lymph nodes in all four species. The virus was detected in pneumocytes type I and II, and ciliated epithelial cells of nasal, bronchial and bronchiolar mucosa. This differs from MERS-CoV where the virus was mainly present in type II pneumocytes<sup>45</sup> (Table1). Replication of the virus was also demonstrated in jejunum, colon,

and rectum<sup>27,36,48</sup>. Viral genome was detected in the blood of rhesus macaques, cynomolgus, and marmoset in one study<sup>45</sup>. Viral replication of nasopharyngeal as well as anal swabs, and lung in old macaques was higher than in young ones<sup>46,47</sup>.

SARS-CoV-2 infection-induced IgG antibodies response against the SARS-CoV-2 spike was noted in all species<sup>36,45,47,48</sup> except in marmoset<sup>45</sup>. The antibodies were protective against a second exposure to the virus. There was no difference between males and females; however, young rhesus macaques had lower antibodies titers than the old macaques<sup>45</sup>. The innate immune response to SARS-CoV-2 infection was variable with normal, high or low leucocytes and lymphocytes counts<sup>36,45</sup>. Occasional reduction of CD4<sup>+</sup> and CD8<sup>+</sup> T cells concentrations was documented<sup>36</sup> as well as transitory release of various cytokines, and chemokines at different days post-inoculation<sup>36,45,48</sup>.

*Drugs and vaccines:* DNA and inactivated virus-based vaccines were evaluated and showed protection in these nonhuman primates. However, the DNA vaccine did not reduce the virus presence in the upper airway, while there was a residual small interstitial pneumonitis in the macaques that received inactivated virus<sup>39,40</sup>. This suggests that none of the vaccines tested so far, displayed a comprehensive protection against SARS-CoV-2 infection. Several candidate DNA vaccines based in various forms of the SARS-CoV-2 Spike (S) protein were also tested in rhesus macaques<sup>38</sup>. The findings revealed that only the vaccine encoding the full-length (S) offered optimal protection against SARS-CoV-2<sup>64</sup>. Nonhuman primates served also for the evaluation of antiviral therapies and medical interventions such as CT- and PET-scanners<sup>46</sup>.

### **Mouse models**

*Viral model:* Wild type mice (BALB/c, C57BL/6); immunodeficient mice (SCID); chimeric mouse expressing human angiotensin-converting enzyme 2 (hACE2), and the RNA-dependent RNA polymerase (SARS1/SARS2-RdRp) were evaluated as models of COVID-19 (Table 2).

Moreover, knockout (KO) mice were generated to test specific immunological pathways or therapy, including ablation of type I (IFN $\alpha$ 1 $^{-/-}$ ) and III interferon (IFN) receptors (IL28r $^{-/-}$ ), signal transducer and activator of transcription 2 (STAT2 $^{-/-}$ ); and serum esterase (Ces1c $^{-/-}$ ).

Patients' isolates of SARS-CoV-2 from different sources and variable times of passaging on various cell cultures or BALB/c mice were employed (Table 2). The multiple passaging on whole animal adapted the virus to the murine ACE-2<sup>53</sup>. SARS-CoV-2 was also modified through the remodeling of the spike receptor-binding domain (RBD), which enhanced its binding efficiency to murine ACE2<sup>51</sup>.

*Phenotype:* The clinical signs and symptoms varied from none to mild weight loss, arched back, and slight bristles. Whole-body plethysmography was used to measure the respiratory function of the animals and showed a mild to moderate reduction in old more than in young (Table 2). Likewise, the pathological changes varied according to the experimental models and included peribronchiolar inflammation, lung edema, moderate multifocal interstitial pneumonia, lymphocytes infiltration, and intra-alveolar hemorrhage. Survival of hACE2 mice was decreased at 5 day post-inoculation and was attributed to high viral replication in the brain, while it was minimal in the lung, suggesting a different pathogenic mechanism of death from human COVID-19<sup>51</sup>. Wild type mice showed no pathology as compared to hACE2 mice, indicating that lack of human ACE2 receptor cannot be infected or inefficiently with SARS-CoV-2<sup>49,55</sup>. On the other hand, mouse-adapted SARS-CoV-2 exhibited more severe pathology, particularly in the aged mouse than hACE2 transgenic mouse, suggesting that these models may be more relevant for the study of human COVID-19<sup>51,53</sup>. However, whether the pathogenesis induced by the mouse-adapted SARS-CoV-2 is translatable to human warrants further studies<sup>51,53</sup>.



*Viral and host interaction:* The virus replicated to high titers in the upper and lower respiratory tract in most of the genetically modified mice models but not in wild type. Viral replication was detected outside the respiratory tract in the intestine of hACE2 mice<sup>49</sup> as well as in the liver, and heart in mouse modified SARS-CoV-2 RBD<sup>51</sup>. Increased viral replication in KO mice IFNar1<sup>-/-</sup> suggested that interferon limited the viral replication<sup>55</sup>.

Specific IgG antibodies against SARS-CoV-2 were documented in two studies (Table 2). The IgG antibodies were found to cross-react in their binding to the spike protein of SARS-CoV, however, with no cross-neutralization, hence suggesting the conservation of the same spike protein epitopes among coronaviruses<sup>52</sup>. Proinflammatory cytokines and chemokines were demonstrated in mouse-adapted SARS-CoV-2, and KO mouse (Table 2). The inflammatory response was significantly higher in the old than young mice.

*Drugs and vaccines:* Antiviral therapies, including remdesivir<sup>54</sup>, IFN lambda<sup>51</sup>, and human monoclonal IgG1 antibody against RBD<sup>49</sup>, were tested in these mouse models and produced a protective effect. Likewise, vaccines using viral particles expressing SARS-2-S protein<sup>51</sup>, or an RBD-based vaccine were tested and showed protection<sup>54</sup>.

## **Hamsters**

*Viral model:* Wild type Syrian hamsters and knockout hamsters for signal transducer and activator of transcription 2 (STAT2<sup>-/-</sup> lacking type I and III interferon signaling) and interleukin 28 receptors (IL28r<sup>-/-</sup> lacking IFN type III signaling) were reported as models for COVID-19. Patients isolate of SARS-CoV-2 from different sources and different passages on various cell cultures were used (Table 3). SARS-CoV-2 was administered intranasally at different titers to anesthetized hamsters. Viral transmission between hamsters was demonstrated either through direct contact or indirectly via airborne transmission.

*Phenotype:* The clinical manifestations included weight loss, which was consistently observed. Other clinical signs and symptoms such as rapid breathing, lethargy, ruffled furs, and hunched back posture were reported in one study<sup>56</sup>. The histopathological findings were variables according to the experimental models and ranged from lung consolidation to multifocal necrotizing bronchiolitis, leukocyte infiltration, and edema. STAT2 *-/-* hamsters exhibited attenuated lung pathology as compared with IL28R-a *-/-* hamsters suggesting that interferon type I response contributed to the injury<sup>55</sup>.

*Viral and host interaction:* The virus replicated to high titer in the upper and lower respiratory tract in most of the hamsters' models. Viral replication was detected in blood and kidney with low concentration (Table 3). STAT2 $-/-$  hamsters had higher titers of infectious virus in the lung, viremia, and high levels of viral RNA in the spleen, liver, and upper and lower gastrointestinal tract in comparison with wild type and IL28R-a *-/-* hamsters. This suggests that IFN type I response limited the replication of SARS-CoV-2 infection. The mechanisms of this conflicting effect namely restricting the virus replication, while in the same time contributing to lung injury remains unclear. Specific IgG antibodies against SARS-CoV-2 were documented in the sera of hamsters at different time-points from virus inoculation ranging from 7 to 21 days. Increased expression of proinflammatory and chemokine genes was demonstrated in the lungs of the SARS-CoV-2 infected animals, however with no increase in circulating levels of proteins such as TNF, interferon- $\gamma$ , and IL-6.

*Drugs and vaccines:* Immunoprophylaxis with early convalescent serum achieved a significant decrease in viral lung load but not in lung pathology<sup>56</sup>.

### **Ferrets, cat, and dog**

*Viral model and phenotype:* Ferrets, cats, and dogs were administered intranasally or intratracheally with various doses and strains of SARS-CoV-2 (Table 4). Ferrets displayed

elevated body temperature for several days associated with signs that differed according to the studies. These include decreased activity and appetite, sporadic cough, and no body weight loss<sup>59-62</sup>. No clinical signs were reported either in cats or in dogs.

*Histopathological changes:* Ferrets exhibited acute bronchiolitis<sup>60,62</sup>, with perivasculitis and vasculitis<sup>62</sup>, but with no discernible pneumonia. Cats disclosed lesions in epithelial nasal, tracheal, and lung mucosa (Table 2).

*Viral and host interaction:* The virus replication and shedding were demonstrated in the upper airways and rectal swabs in ferrets and cats, but the extent to other tissues varied in ferrets from none to multiple organs, including lung, blood, and urine. No viral RNA was detected in cats' lungs. Dogs showed RNA positive rectal swab but none in upper or lower airways. Viral transmission between ferrets and cats was demonstrated either through direct contact<sup>54</sup> or indirectly via airborne route<sup>61</sup>.

Ferrets, cats, and dogs exhibited specific antibody response against SARS-CoV-2<sup>59,61,62</sup>. A study of the ferret immune response to SARS-CoV-2 revealed a subdued low interferon type I and type III response that contrasts with increased chemokines and proinflammatory cytokine IL6, which is reminiscent of the human response<sup>60</sup>.

## **Discussion**

This systematic review of experimental animal models of SARS-CoV-2 induced- COVID-19 identified 13 peer-reviewed studies and 14 preprints that reported data on nonhuman primates<sup>36-48</sup>, mice<sup>49-55</sup>, hamsters<sup>55-58</sup>, ferrets<sup>59-62</sup>, cats and dogs<sup>62</sup> models of COVID-19. The main findings indicate that most of the animal models could mimic many features of mild human COVID-19 with a full recovery phenotype<sup>3</sup>. They also revealed that older animals display relatively more severe illness than the younger ones<sup>37,45,47,51,53</sup>, which evokes human

COVID-19<sup>3,65</sup>. However, none of the animal models replicated the severe or critical patterns associated with mortality as observed in humans with COVID-19<sup>3</sup>.

The results of this systematic review are consistent with studies of animal models of SARS-CoV-2 and MERS-CoV, which failed to replicate the full spectrum of humans' illness<sup>66,67</sup>. Nonetheless, several features of mild COVID-19 in humans could be mirrored. High viral titers in the upper and lower respiratory tract and lung pathology were demonstrated in both large and small animal models. The pathology encompassed mild interstitial pneumonia, consolidation, and diffuse alveolar damage, albeit localized to small lung area, edema, hyaline membrane formation, and inflammation. SARS-CoV-2 elicited specific antibodies response against various viral proteins in the sera of most of the animal models.

This systematic review revealed that none of these newly established animal models replicated the common complications of human COVID-19 such as ARDS and coagulopathy<sup>26-32,65,68,69</sup>. ARDS can be particularly severe and results in refractory hypoxemia requiring maximum respiratory supportive measures in intensive care unit<sup>65,68,69</sup>. The coagulopathy can lead to severe complications such as massive pulmonary embolism, cerebrovascular stroke, and mesenteric infarction, including in younger people<sup>26,27,31,32</sup>. The pathology underlying these two complications were recently revealed by post-mortem studies disclosing diffuse alveolar damage involving the whole lung, hyaline membrane formation, and infiltration with inflammatory cells, thus leaving no air space open for ventilation<sup>12,13,64,70,71</sup>. It also detected the presence of diffuse and widespread thrombosis in the micro- and macro-circulation, including the pulmonary circulation compromising the lung perfusion<sup>12,13</sup>. This double hit affecting the ventilation and perfusion simultaneously underlies the intractable hypoxemia that contributed to the high mortality. None of the animal models replicated the respiratory failure, thromboembolic manifestations, and their pathological

expression, hence, indicating that a wide gap separates the animal models from the full spectrum of COVID-19 in humans.

The mechanisms of the lung injury and coagulopathy are not well understood, although several known pathways were postulated including cytokines storm leading to upregulation of tissue factor<sup>20-22</sup>, activation/injury of the endothelium infected by the virus<sup>29,68,72</sup>, complement activation<sup>73</sup>, alveolar hypoxia promoting thrombosis<sup>74</sup>, and autoantibodies against phospholipid and lupus anticoagulant<sup>75,76</sup> modulating the hemostasis and coagulation cascade directly. Hence, the development of animal models that replicate the dysregulation of the inflammation and coagulation could be important, as these would allow the deciphering of the intimate mechanisms at play. This, in turn, may aid in identifying therapeutic targets and the testing of immunotherapy, anticoagulation, and thrombolytic interventions and thereby may improve the outcome.

Both antiviral and vaccine therapies were tested in rhesus macaques and mice infected with SARS-CoV-2<sup>39-41</sup>. The antiviral drug stopped the viral replication and improved the pneumonitis<sup>41,54</sup>. The vaccines induced an increase in titers of neutralizing antibodies in the sera that correlated with the decrease of viral replication and prevented the lung pathology<sup>38-40</sup>. These results represent a substantial proof of the concept of antiviral or vaccine efficacy against SARS-CoV-2 in animal models. However, because of the lack of overt clinical illness, the rapid clearance of the virus, and spontaneous improvement of the pneumonitis without lethality, the models do not permit the full assessment of the duration of the protection of the vaccines, or the effect of antiviral therapy on survival.

Since the emergence of SARS-CoV infection in 2003<sup>77</sup>, followed by the MERS-CoV in 2012<sup>78</sup>, and now with COVID-19, researchers have not been able to develop a model of coronavirus infection that reproduces the severity and lethality seen in humans<sup>66,67</sup>. One of the well-known reasons lies in the difference of ACE-2 receptor binding domain structure across

species<sup>79</sup>. Human and old-world primates have conserved a comparable structure that allows binding with high affinity to the SARS-CoV-2<sup>79</sup>. The new-world primates, hamsters, ferrets, and cats maintained an intermediate affinity, while mice exhibit very low affinity<sup>79</sup>. The latter explains why wild-type mouse does not support SARS-CoV-2 replication, and hence, the necessity to create a chimera that expresses human ACE-2, to enable the use of this species as model of COVID-19<sup>49</sup>. More recently, a study applying single-cell RNA sequencing to nonhuman primate uncovered another explanation that may underlies the difference between old-world primates and humans in expressing the complex phenotype of COVID-19<sup>80</sup>. The study reveals that the cellular expression and distribution of ACE2 and TMPRSS2 which are essential for virus entry in the cells and its spread inside the body differ in the lung, liver, and kidney between the two species. ACE2 expression was found lower in pneumocytes type II and higher in ciliated cells in nonhuman primate lung as compared to humans<sup>39</sup>. This is particularly significant as type II pneumocytes are critical targets of SARS-CoV-2 in humans and the pathogenesis of lung injury/damage. Finally, the innate immune response including the defense system against viruses diverged during evolution both at the transcriptional levels and cellular levels, which may also explain why the SARS-CoV-2 hardly progresses in these animals outside the respiratory system<sup>81</sup>. Taken together, these fundamental differences represent a real challenge to the successful development of an animal model that reproduces human COVID-19.

This systematic review has few limitations. First, it is the high number of preprints included in this study that have not been peer-reviewed. Second, the animal models from the same species were difficult to compare across studies, as they used different viral strain, inoculum size, route of administration, and timing of tissue collection.

In conclusion, this systematic review revealed that animal models of COVID19 mimic mild human COVID-19, but not the severe form COVID-19 associated with mortality. It also

disclosed the knowledge generated by these models of COVID-19 including viral dynamic and transmission, pathogenesis, and testing of therapy and vaccines. Likewise, the study underlines the distinct advantages and limitations of each model, which should be considered when designing studies, interpreting pathogenic mechanisms, or extrapolating therapy or vaccines results to humans. Finally, harmonization of animal research protocols to generate results that are consistent, reproducible, and comparable across studies is needed.

## Reference

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**(7798): 270-3.
2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine* 2020; **382**(8): 727-33.
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama* 2020.
4. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. *Nature* 2020.
5. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (New York, NY)* 2020; **367**(6483): 1260-3.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**(2): 271-80.e8.
7. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature medicine* 2020; **26**(5): 681-7.
8. Muus C, Luecken MD, Eraslan G, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. *bioRxiv* 2020: 2020.04.19.049254.
9. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* 2020; **181**(5): 1016-35.e19.
10. Li C, Ji F, Wang L, et al. Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China. *Emerging infectious diseases* 2020; **26**(7).
11. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *The New England journal of medicine* 2020; **382**(10): 970-1.
12. Bradley BT, Maioli H, Johnston R, et al. Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections. *medRxiv* 2020: 2020.04.17.20058545.
13. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Annals of internal medicine* 2020.
14. Horton R. Offline: A global health crisis? No, something far worse. *Lancet (London, England)* 2020; **395**(10234): 1410.



15. university JH. Global death from COVID-19. 2020. <https://coronavirus.jhu.edu/map.html> (accessed 05 July 2020).
16. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA cardiology* 2020.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* 2020; **395**(10229): 1054-62.
18. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious diseases* 2020; **20**(6): 656-7.
19. Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nature medicine* 2020; **26**(4): 453-5.
20. Zhou Z, Ren L, Zhang L, et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. *Cell host & microbe* 2020.
21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)* 2020; **395**(10223): 497-506.
22. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *The Journal of clinical investigation* 2020; **130**(5): 2620-9.
23. Liu B, Han J, Cheng X, et al. Persistent SARS-CoV-2 presence is accompanied with defects in adaptive immune system in non-severe COVID-19 patients. *medRxiv* 2020: 2020.03.26.20044768.
24. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cellular & molecular immunology* 2020; **17**(5): 533-5.
25. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal transduction and targeted therapy* 2020; **5**(1): 33.
26. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. *Radiology* 2020: 201544.
27. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive care medicine* 2020: 1-10.
28. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis research* 2020; **191**: 145-7.
29. Poor HD, Ventetuolo CE, Tolbert T, et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. *Clinical and Translational Medicine*; **n/a**(n/a).

30. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. *Journal of thrombosis and haemostasis : JTH* 2020.
31. Bhayana R, Som A, Li MD, et al. Abdominal Imaging Findings in COVID-19: Preliminary Observations. *Radiology* 2020: 201908.
32. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *The New England journal of medicine* 2020; **382**(20): e60.
33. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of thrombosis and haemostasis : JTH* 2020; **18**(5): 1094-9.
34. Lakdawala SS, Menachery VD. The search for a COVID-19 animal model. *Science (New York, NY)* 2020; **368**(6494): 942-3.
35. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine* 2009; **6**(7): e1000097.
36. Munster VJ, Feldmann F, Williamson BN, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. *Nature* 2020.
37. Yu P, Qi F, Xu Y, et al. Age-related rhesus macaque models of COVID-19. *Animal models and experimental medicine* 2020; **3**(1): 93-7.
38. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science (New York, NY)* 2020.
39. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. *bioRxiv* 2020: 2020.05.13.093195.
40. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science (New York, NY)* 2020: eabc1932.
41. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. *bioRxiv* 2020: 2020.04.15.043166.
42. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science (New York, NY)* 2020.
43. Bao L, Deng W, Gao H, et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. *bioRxiv* 2020: 2020.03.13.990226.
44. Deng W, Bao L, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* 2020: 2020.03.13.990036.
45. Lu S, Zhao Y, Yu W, et al. Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* 2020: 2020.04.08.031807.

46. Finch CL, Crozier I, Lee JH, et al. Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (*Macaca fascicularis*). *bioRxiv* 2020: 2020.05.14.096727.
47. Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science (New York, NY)* 2020; **368**(6494): 1012-5.
48. Woolsey C, Borisevich V, Prasad AN, et al. Establishment of an African green monkey model for COVID-19. *bioRxiv* 2020: 2020.05.17.100289.
49. Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* 2020.
50. Li W, Drelich A, Martinez DR, et al. Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models. *bioRxiv* 2020: 2020.05.13.093088.
51. Dinno KH, Leist SR, Schäfer A, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. *bioRxiv* 2020: 2020.05.06.081497.
52. Lv H, Wu NC, Tsang OT, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. *Cell reports* 2020; **31**(9): 107725.
53. Gu H, Chen Q, Yang G, et al. Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy. *bioRxiv* 2020: 2020.05.02.073411.
54. Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. *bioRxiv* 2020: 2020.04.27.064279.
55. Boudewijns R, Thibaut HJ, Kaptein SJF, et al. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters. *bioRxiv* 2020: 2020.04.23.056838.
56. Chan JF-W, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clinical Infectious Diseases* 2020.
57. Rogers TF, Zhao F, Huang D, et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. *bioRxiv* 2020: 2020.05.11.088674.
58. Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* 2020.
59. Kim YI, Kim SG, Kim SM, et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell host & microbe* 2020; **27**(5): 704-9.e2.
60. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 2020; **181**(5): 1036-45.e9.


61. Richard M, Kok A, de Meulder D, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv* 2020: 2020.04.16.044503.
62. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science (New York, NY)* 2020; **368**(6494): 1016-20.
63. Zhao Y, Wang J, Kuang D, et al. Susceptibility of tree shrew to SARS-CoV-2 infection. *bioRxiv* 2020: 2020.04.30.029736.
64. Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. *Journal of Clinical Pathology* 2020; **73**(5): 239-42.
65. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *Jama* 2020; **323**(16): 1574-81.
66. Subbarao K, Roberts A. Is there an ideal animal model for SARS? *Trends in microbiology* 2006; **14**(7): 299-303.
67. Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. *Virology* 2015; **479-480**: 247-58.
68. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *The New England journal of medicine* 2020.
69. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. *Jama* 2020.
70. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory medicine* 2020; **8**(4): 420-2.
71. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. *Lancet (London, England)* 2003; **361**(9371): 1773-8.
72. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet (London, England)* 2020; **395**(10234): 1417-8.
73. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. *Annals of diagnostic pathology* 2020; **46**: 151530.
74. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. *Thrombosis research* 2019; **181**: 77-83.
75. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *The New England journal of medicine* 2020; **382**(17): e38.
76. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. *The New England journal of medicine* 2020.
77. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *The New England journal of medicine* 2003; **348**(20): 1986-94.

78. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. *New England Journal of Medicine* 2012; **367**(19): 1814-20.
79. Damas J, Hughes GM, Keough KC, et al. Broad Host Range of SARS-CoV-2 Predicted by Comparative and Structural Analysis of ACE2 in Vertebrates. *bioRxiv* 2020: 2020.04.16.045302.
80. Han L, Wei X, Liu C, et al. Single-cell atlas of a non-human primate reveals new pathogenic mechanisms of COVID-19. *bioRxiv* 2020: 2020.04.10.022103.
81. Hagai T, Chen X, Miragaia RJ, et al. Gene expression variability across cells and species shapes innate immunity. *Nature* 2018; **563**(7730): 197-202.

### **Box 1. Search strategy and selection criteria**

We searched the Medline, as well as BioRxiv and MedRxiv preprint servers for original research describing or using an animal model of SARS-CoV-2 induced COVID published in English from January 1, 2020, to May 20, 2020. We used the search terms “COVID-19” OR “SARS-CoV-2” AND, “animal models”, “hamsters”, “nonhuman primates”, “macaques”, “rodent”, “mice”, “rats”, “ferrets”, “rabbits”, “cats”, and “ dogs”. The preprint servers were included in the search as the field of COVID-19 is developing quickly. Inclusion criteria were establishment of animal models of COVID-19 as endpoint. Other inclusion criteria were assessment of prophylaxis, therapies, or vaccines, using animal models of COVID-19. 101 studies and 326 preprints were screened, of which 13 peer-reviewed studies and 14 preprints were included in the final analysis (Fig.1). The variables extracted were the population type, study aim, the virus strain used, clinical response, pathology, viral replication, and host response as well as the effects of prophylaxis, drugs, or vaccines. The outcomes were organized according to species and categorized into phenotype (signs or symptoms; histopathology, time-course of the illness and outcome), viral (titer in each tissue organ, detection methods, duration of positivity), and host response (dynamic of seroconversion, inflammatory and hemostatic markers), therapy and vaccine (efficacy, and safety).

**Figure 1. Flow diagram illustrating the process of studies selection \***



**Table 1. Summary of studies using nonhuman primate models of COVID-19**

Species (ref)	Number Age (Gender)	Virus strain Dose* (Inoculation Route)†	Clinical signs	Viral replication‡ (DPI) §	Pathology (DPI)	Immune response	Seroconversion (DPI)	Outcome Measures
<b>Rhesus macaques</b> Munster, V. et al (2020) <sup>36</sup>	n=8 Adults (M/F)	SARS-CoV-2 nCoV-WA1-2020 4×10 <sup>5</sup> TCID <sub>50</sub> (IT, IN, PO)	Fever Weight loss Dyspnea Tachypnea Piloerection Reduced appetite Hunched posture Pale appearance Dehydration	Nose, oropharynx, lung Rectum (1)	Anemia Mild to moderate, interstitial pneumonia, Edema Hyaline membranes formation Hyperplasia type II pneumocytes Swollen mediastinal lymph nodes Distended intestine	At 1 dpi only, significant increases in IL1ra, IL6, IL10, IL15, MCP-1, MIP-1b  At 3 dpi decrease in TGFα	IgG antibody anti-spike protein (10)	Pathogenesis of COVID-19
<b>Rhesus macaques</b> Yu, P. et al (2020) <sup>37</sup>	n=3 3-5 y  n=2 15 y (NA)□	BetaCoV/Wuhan/IVDC-HB-01/2020  1 × 10 <sup>6</sup> TCID <sub>50</sub> (IT)	Weight loss Asthenia  More severe in old than young	Nose, oropharynx, lung rectum, alveolar epithelia macrophages ( 3)  Higher replication in old than young	Interstitial pneumonia Inflammation Edema  More severe in old than young	Decreased CD4+ T and CD8+ T cells in young and old.	IgG antibody anti- SARS-CoV-2 (14)	Pathogenesis of COVID-19 in aging animals
<b>Rhesus macaques</b> Yu, J. et al (2020) <sup>38</sup>	n=4 per group (6 vaccinated groups) 6-12 years (M/F)  n=10 sham control  6-12 years (M/F)	DNA vaccine IM at week 0 and week 3  1.1x10 <sup>4</sup> PFU (IN and IT) (day 21 post-vaccine)  1.1x10 <sup>4</sup> PFU (IN and IT)	NA □	Lowest BAL levels of viral RNA with full-length S protein encoding vaccine  High BAL levels of viral RNA	NA  NA	Upregulation IFN-γ anti-peptide spike proteins.  S1 and RBD lower response than other variant Spike proteins**  Anamnestic humoral and cellular immune responses including IFN-γ ELISPOT responses	IgG antibody anti- SARS-CoV-2 (day14 post-vaccination)  NA	Evaluation candidate DNA vaccine
<b>Rhesus macaques</b> Van Doremalen, N. et al (2020) <sup>39</sup>	n=6 vaccine M/F	2.5 x 10 <sup>10</sup> ChAdOx1 nCoV-19 ( IM)  SARS-CoV-2 nCoV-WA1-2020  2.6 × 10 <sup>6</sup> TCID <sub>50</sub> (IT, IN, PO, CJ) (day 28 post-vaccine)	Tachypnea (3/6), Dyspnea (2/6), Ruffled fur (1/6)	Nose, BAL (2/6), Lung (very low), oropharynx, mediastinal, duodenum (3)  No BAL subgenomic viral RNA	NO	Upregulation of IFN-γ (1 dpi)  No difference in TNF-α, IL-2, IL-4, IL-6, and IL-10 vaccine vs. control	IgG antibody anti-SARS-CoV-2 spike protein (day 14 post-vaccination)	Evaluation of DNA vaccine



	n=3 control M/F	Vaccinated with $2.5 \times 10^{10}$ ChAdOx1 GFP (IM)  SARS-CoV-2 nCoV-WA1-2020  $2.6 \times 10^6$ TCID <sub>50</sub> (IT, IN, PO, CJ) (day 28 post-vaccine)	Tachypnea (3/3) Ruffled fur (2/3) Diarrhea (1/3) Pale appearance (1/3) Red nose (1/3)	BAL, nasal swabs, lung, cervical, mediastinal Lymph nodes, duodenum, urinary bladder  BAL subgenomic viral RNA (3&5 dpi)	Interstitial pneumonia (2 of 3) Thickening of alveolar septae Edema Hyperplasia type I & II pneumocytes Syncytial cells	TNF- $\alpha$ , IL-2, IL-4, IL-6, and IL-10	NA	
<b>Rhesus macaques</b>	n=4 per vaccine group  3-4 years (M/F)	PiCoVacc 6 $\mu$ g/dose (high) or 3 $\mu$ g/dose (low) at 0, 7, and 14 days (IM)  SARS-CoV-2-human/CHN/CN1/2020  $1 \times 10^6$ TCID <sub>50</sub> (IT) (day 22 post-vaccine)	NA	Pharyngeal, anal, and pulmonary (3)	Mild and focal histopathological changes both lower lobes	No differences CD3+, CD4+, CD8+, TNF- $\alpha$ , IFN- $\gamma$ , IL-2, IL-4, IL-5, IL-6 vaccine vs. control	IgG antibody anti-SARS-CoV-2 (Day 14 post-vaccination)	Evaluation of an inactivated vaccine
Gao, Q. et al (2020) <sup>40</sup>	n=4 control  3-4 years (M/F)	Vaccinated with Al(OH) <sub>3</sub> adjuvant (sham) or physiological saline (control) at 0, 7, and 14 days IM  SARS-CoV-2-human/CHN/CN1/2020  $1 \times 10^6$ TCID <sub>50</sub> (IT) (22 days post-vaccine)	NA	Oropharynx, crissum, lung, rectum (3)	Severe interstitial pneumonia	CD3+, CD4+, CD8+, TNF- $\alpha$ , IFN- $\gamma$ , IL-2, IL-4, IL-5, IL-6		
<b>Rhesus macaques</b>	n=6 Remdesivir (M/F)	SARS-CoV-2 nCoV-WA1-2020  $2.6 \times 10^6$ TCID <sub>50</sub> (IT, IN, OC, PO)	Dyspnea (1/6)	Nose, oropharynx, lung (1) Low BAL titers (1) No virus in BAL (3)	Minimal interstitial pneumonia subpleural spaces (3/6)	NA	NA	Testing of antiviral therapy
<b>Rhesus macaques</b>	n=6 control  (M/F)	Vehicle solution  SARS-CoV-2 CoV-WA1-2020  $2.6 \times 10^6$ TCID <sub>50</sub> (IT, IN, OC, PO)	Tachypnea, Dyspnea	Nose, oropharynx, lung, and BAL (1)	Multifocal, mild to moderate, interstitial pneumonia	NA	NA	
Williamson, B.N. et al (2020) <sup>41</sup>								

<b>Rhesus macaques</b>	n=9 6-12 years (M/F)	SARS-CoV-2 USA-WA1/2020  initial inoculation $1.1 \times 10^6$ n=3 $1.1 \times 10^5$ n=3 $1.1 \times 10^4$ PFU n=3 (IN, IT)	Reduced appetite	Nose, pharynx, trachea, lung, gastrointestinal tract, liver, kidney, pneumocytes I & II, ciliated bronchial epithelial cells (1)	Acute interstitial pneumonia Consolidation Edema Multiple Inflammatory foci Hyaline membranes Damage to type I and type II pneumocytes Necrotic bronchiolar epithelium Bronchiolar epithelial syncytial cells	Neutropenia Lymphopenia (mild and transitory in high dose group)  IFN- $\gamma$ upregulation	IgG anti- SARS-CoV-2 Spike protein ( 35)	Immune protection after a second exposure
Chandrashekar, A. et al (2020) <sup>42</sup>	n = 9 6-12 years (M/F)	SARS-CoV-2 USA-WA1/2020  Second inoculation day 35 post-initial infection $1.1 \times 10^6$ $1.1 \times 10^5$ $1.1 \times 10^4$ PFU (IN, IT)	No	5 log <sub>10</sub> reduction BAL & nasal viral loads ( 1 )	No	Increased virus-specific Nab titers		Immune protection after a second exposure
<b>Rhesus macaques</b>	n=7 3-5 years (NA)	SARS-CoV-2 WH-09/hum/2020  Initial inoculation $1 \times 10^6$ TCID <sub>50</sub> (IT)	Fever Weight loss Posture change Rapid breathing Reduced appetite	Nose, oropharynx, lung, gut, spinal cord, bladder, rectum ( 3 )	Thickened alveolar septa Macrophages accumulation in alveoli Degeneration alveolar epithelia Inflammatory infiltrates	Increase CD4+ T cells	IgG antibody anti-SARS-CoV-2 (14)	Immune protection after a second exposure
Bao, L. et al (2020) <sup>43</sup>	(n=4) 3-5 years (NA)	SARS-CoV-2 WH-09/hum/2020  second inoculation day 28 post-initial infection  $1 \times 10^6$ TCID <sub>50</sub> (IT)	Transient temperature increase	Negative	No pathology	CD4+ T higher at 7 day post – exposure vs. post-initial exposure	Higher IgG antibody anti-SARS-CoV-2 ( 14) vs. initial exposure	Immune protection after a second exposure
<b>Rhesus macaques</b>	(n=5) 3-5 y (M)	SARS-CoV-2 WH-09/hum/2020  $1 \times 10^6$ TCID <sub>50</sub> (IT, CJ, IG)	weight loss (IT route)	Nasal, oropharynx, rectum (IG route) Conjunctival (CJ route) Lung, ileum, caecum (IT) (1)	Interstitial pneumonia (IT route) Mild interstitial pneumonia (CJ route) No pneumonia (IG route)	NA	IgG anti- SARS-CoV-2 on 21 dpi (CJ route)	Viral infection routes
<b>Rhesus macaques</b>	n=4 young n=6 adult n=4 old (NA)	SARS-CoV-2 CDC, Guangdong, China  $4.75 \times 10^6$ PFU (IT, IN, CJ) (50% given to young)	Fever Weight loss	Nose, oropharynx, trachea bronchus, lung, rectum blood, spleen ( 2 )	Inflammatory cells infiltrates Diffuse hemorrhage and necrosis Swollen lymph nodes (hilar, mediastinal, mesenteric) Pericardial effusion Mild hepatic steatosis splenic hemorrhage	Peak CD4+ T cells, CD8+ T cells, and monocytes (2)  Young stronger B cell responses vs. adults vs. old  Increased G-CSF, IL-1A, IL-8, IL-15, IL-18, MCP-1, MIP-1B, sCD40-L	IgG antibody anti- SARS-CoV-2 ( 4)  IgG levels lower in young vs. adult vs. old	Pathogenesis of COVID-19 in Old and New-world primates



<b>African green monkey</b>	n=6 NA	SARS-CoV-2-INMI1- /2020/Italy	reduced appetite fever	Nasal, oropharynx, lung, rectum, pneumocytes I &II, alveolar macrophages (2)	Interstitial pneumonia Bronchiolitis Edema Hemorrhage Hyaline membrane Hyperplasia type II pneumocytes Distention and flaccidity small intestines segments	Increased CRP¶ (n =2)  IL-8, IP-10, IL-12, IL-6, IFN- beta, IL10, and MCP-1 (2 dpi)	IgG antibody against SARS- CoV-2 b (5 )	Pathogenesis of COVID-19
Woolsey, C. et al (2020) <sup>48</sup>		5x10 <sup>5</sup> PFU (IT, IN)						

\***TCID<sub>50</sub>**: Median Tissue Culture Infectious Dose at which 50% of the cells are infected; **PFU**: plaque-forming unit. †**IT**: intratracheal; **IN**: intranasal; **CJ**: intraconjunctival; **OC**: ocular; **IG**: intragastric, **PO**: per oral. ‡ **Viral replication**: RNA copies (PCR), viral antigen (immunostaining), viral particles (electron microscopy). § **dpi**: day post-inoculation. ¶ **CRP**: C-reactive protein. || **NA**: Not available. \*\***Vaccine encoding spike protein variants**: Full-length SARS-CoV-2 S protein, S.dCTM: Deletion of the cytoplasmic tail of SARS-CoV-2 S protein, S.dTM: Deletion of the transmembrane domain and cytoplasmic tail reflecting the soluble ectodomain, S1: S1 domain with a fold on trimerization tag, RBD: Receptor-binding domain with a fold on trimerization tag, S.dTM.PP: A prefusion stabilized soluble ectodomain with deletion of the furin cleavage site, two proline mutations, and a fold on trimerization tag. IM: Intramuscular

**Table 2. Summary of studies using mice models of COVID-19**

Species (ref)	Number Age (Gender)	Virus strain Dose* (Inoculation Route)†	Clinical signs	Viral replication‡ (DPI) §	Pathology (DPI)	Immune response	Seroconversion (DPI)	Outcome Measures
<b>Mice</b> <b>BALB/c:</b> <b>WT¶</b> <b>SCID  </b> <b>C57BL/6:</b> <b>WT</b> <b>Ifnar1-/-</b> <b>IL28r-/-</b>	WT-BALB/c n=3 SCID n=3	2 × 10 <sup>5</sup> TCID <sub>50</sub> of P 4†† or 2 × 10 <sup>6</sup> of P 6†† (IN)	NA	Lung (3)  No difference in viral load WT vs. SCID	Mild lung pathology (2)  No difference in lung pathology WT vs. SCID	Mild inflammatory response	NA	Interferon response to SARS-CoV infection
	6-8 weeks (F)							
	C57BL/6 n=5 Ifnar1-/- <sup>¶¶</sup> n=14	2 × 10 <sup>5</sup> TCID <sub>50</sub> of P 4 or 2 × 10 <sup>6</sup> of P 6 (IN)	NA	Lung (3)  higher viral replication in Ifnar1-/- mice vs. WT and IL28r-/- mice	Greater intra-alveolar hemorrhage and peribronchiolar inflammation in Ifnar1-/- mice than WT and IL28r-/- mice (3)	higher inflammatory response in Ifnar1-/- vs. WT and IL28r-/- mice	NA	
Boudewijns, R., et al (2020) <sup>55</sup>	C57BL/6 n=5 IL28r-/- n=5	2 × 10 <sup>5</sup> TCID <sub>50</sub> of P 4 or 2 × 10 <sup>6</sup> of P 6 (IN)	NA	Lung (3)  No difference in viral load between WT and IL28r-/-	Mild lung pathology (3)	mild inflammatory response	NA	
<b>Mice</b> <b>hACE2□□</b> <b>transgenic mice</b>	hACE2 mice (ACE2-HB-01) n=19 6-11 months (M/F)	SARS-CoV-2 (BetaCoV/Wuhan/IVDC-HB-01/2020 EPI_ISL_402119) 10 <sup>5</sup> TCID <sub>50</sub> (IN)	Slight bristles Weight loss Arched back	Highest viral load in Lung (3) Intestine (1) alveolar macrophage, and alveolar epithelia (3)	Moderate interstitial pneumonia Thickened alveolar septa Lymphocytes, macrophages, and monocytes infiltrates in the interstitial and alveolar space Bronchioles degeneration (3)  No pathology in intestine, spleen, heart, liver, kidney, brain, and testis	MAC2, CD3+ T and CD19+ B cells in alveolar septum	IgG antibody response against SARS-CoV-2 (21)	Pathogenesis of COVID-19
	WT-HB-01 (n=15) 6-11 months (M/F)	SARS-CoV-2 (BetaCoV/Wuhan/IVDC-HB-01/2020 EPI_ISL_402119) 10 <sup>5</sup> TCID <sub>50</sub> (IN)	No	No viral RNA detectable in lung or intestine (1)	No	No	No	
	Mock-treated hACE2 mice (n=15) 6-11 months (M/F)	PBS 50 μl (IN)	No	No viral RNA detectable in lung or intestine	No	No	No	
<b>Mice</b> <b>BALB/c:</b> <b>WT</b>	n=5 6-8 weeks (M)  Infection	SARS-CoV-2 (BetaCoV/Hong Kong/VM20001061/2020 [KH1])  SARS-CoV (HK39849,	NA	NA	NA	NA	IgG antibody response against SARS-CoV and SARS-CoV-2 spike protein and RBD	Cross-reactivity of antibodies against SARS-CoV and SARS-
Lv, H., et al (2020) <sup>52</sup>								

		SCoV)						CoV-2
		10 <sup>5</sup> PFU (IN)						
	n=5 6-8 weeks (M) Immunization	Immunization with heat-inactivated plasma from SARS-CoV and SARS-CoV-2 (IP)	NA	NA	NA	NA	cross-reactive antibody binding responses SARS-CoV-2 and SARS-CoV  No cross-neutralization SARS-CoV-2 and SARS-CoV	
	n=6 6-8 weeks (M) control	vehicle (IN)	NA	NA	NA	NA		
<b>Transgenic Mice C57BL/6<sup>***</sup>: Ces1c<sup>-/-</sup></b>	n=7 17 weeks (F) Remdesivir	SARS1/SARS2-RdRp §§ 10 <sup>3</sup> PFU (IN)  Remdesivir given at 1dpi	Improvement of pulmonary function	reduced lung viral load 10 <sup>2</sup> PFU/lobe (5)	Decreased lung hemorrhage (5)	NA	NA	Antiviral therapy testing
	n=7 17 weeks (F) Control	SARS1/SARS2-RdRp 10 <sup>3</sup> PFU (IN)  vehicle	Reduced pulmonary function by WPH†††	Lung viral load 10 <sup>5</sup> PFU/lobe (5)	Lung hemorrhage (5)	NA	NA	
Pruijssers, A.J., et al (2020) <sup>54</sup>	n=7 17 weeks (F) Control	SARS1/SARS2-RdRp 10 <sup>3</sup> PFU (IN)  vehicle	Reduced pulmonary function by WPH†††	Lung viral load 10 <sup>5</sup> PFU/lobe (5)	Lung hemorrhage (5)	NA	NA	
<b>Mice BALB/c: WT</b>	n=3 Young, 6 weeks (F)	Mouse-adapted SARS-CoV-2 (BetaCoV/Wuhan/AMM S01/2020)	Weight loss old mice (5)	Trachea, lung, heart, liver and intestine, pneumocytes Type II	Thickened alveolar septa Alveolar damage and focal exudation Hemorrhage, Inflammatory cell infiltration Denaturation of endothelial tissues (3)	Increased TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IL-5, MCP-1, G-CSF, and GM-CSF (3)	NA	Establishment of mouse-adapted SARSCoV-2 model of COVID19
	n=3 Old, 9 months (F)	7.2×10 <sup>5</sup> PFU (IN)		Viral replication similar in old vs. young cells (3)	Lung pathology similar in old vs. young mice	Higher and sustained cytokines levels in aged mice vs. young		
Gu, H., et al (2020) <sup>53</sup>	Control mice  NA	NA	No weight loss	No viral protein	NO	NO		Evaluation of candidates vaccine

	n=10 6-8 weeks immunized with SARS-CoV-2 RBD- Fc protein	Immunization day 1, 14  Challenged with mouse adapted SARS-CoV-2 (IN), 4weeks after second immunization	NA	No viral replication detectable in lungs (5)	No	NA	Higher IgG antibody response against SARS-CoV-2 (14)
	PBS control with aluminum adjuvant			High viral load in the trachea and lungs (5)	Focal perivascular and peribronchiolar inflammation  Thickened alveolar septa	NA	NA
<b>Mice C3B6: hACE2 transgenic mice and BALB/c mice</b>	n=5 6-9 weeks (F) C3B6: hACE2 mice Immunization	SARS-CoV-2 10 <sup>5</sup> PFU (IN)  human monoclonal IgG1 antibody (12h) prior the virus challenges (IP)	No	No viral replication detectable in lung (2)	NA	NA	IgG1 ab1 protects hACE2 transgenic mice from SARS- CoV-2 infection.
	n=6 6-9 weeks (F) C3B6: hACE2 mice Control	SARS-CoV-2 10 <sup>5</sup> PFU (IN)  IgG1 m336 (no activity in vitro)	No	Viral replication 10 <sup>3</sup> PFU per lung (2)	NA	NA	No
	Balb/c n=5 10-12 months (F)	mouse ACE2 adapted SARS-CoV-2 <sup>‡‡</sup>  10 <sup>5</sup> PFU (IN)  human monoclonal IgG1 ab1 antibody (12h) prior the virus challenges (IP)	No	No viral replication detectable in lung lobe at different dosages (2)	NA	NA	IgG1 ab1 protected mice SARS-CoV-2 challenge
Li, W., et al (2020) <sup>50</sup>	hACE2 mice  NA	SARS-CoV-2 10 <sup>5</sup> PFU (IN)	Weight loss Mortality 40% (5)	Lung (2), brain (5)	NA	NA	NA
<b>Mice BALB/c: And hACE2 transgenic mice</b>	BALB/c mice n=33 Young 12 weeks	SARS-CoV-2MA <sup>§</sup> 10 <sup>5</sup> PFU (IN)	Pulmonary obstruction (WBP)	upper airway lung (2,4)	Greater lung inflammation and hemorrhage in old vs. young mice (2,4)	NA	NA
Dinnon, K.H., et al (2020) <sup>51</sup>	BALB/c mice n=34 12 months		Greater weight and pulmonary function loss	higher replication in old vs. young mice			Evaluation of vaccine and therapy in mouse- adapted SARS-CoV-2 model

		in old vs. young mice				
Vaccination n=8-10 10 weeks BALB/c	SARS-CoV-2 spike (S) or nucleocapsid (N)  challenged 4 weeks post- inoculation with SARS- CoV-2 MA 10 <sup>5</sup> PFU (IN)	NA	vaccine with spike S reduced lung and nasal turbinate titer (2)	NA	NA	NA
Prophylaxis and therapy BALB/c 12 weeks n=NA	Subcutaneous administration interferon (IFN) lambda-1a 2μg 18hr prior or 12hr after SARS-CoV-2 MA 10 <sup>5</sup> PFU (IN)		Reduced SARS-CoV-2 MA replication in the lung (2)	NA	NA	NA

\***TCID<sub>50</sub>**: Median Tissue Culture Infectious Dose at which 50% of the cells are infected; **PFU**: plaque-forming unit. † IN: intranasal; IP: intraperitoneal. ‡ **Viral replication**: RNA copies (PCR), viral antigen (immunostaining), viral particles (electron microscopy). § **dpi**: day post-inoculation. ¶ **WT**: Wild Type. || **SCID**: Severe combined immunodeficiency (lacking functional T and B cells). \*\* **SARS-CoV-2MA** A recombinant mouse ACE2 adapted SARS-CoV-2 variant remodeled by introduction of two amino acid changes at the ACE2 binding pocket in the receptor binding domain to facilitate efficient binding to mouse ACE2. †† **P4 and P6**: Number of serial passaging of patient SARS-CoV-2 on HuH7 and Vero-E6 cells. ‡‡ **Remodeling of the SARS-CoV-2 spike protein** in the receptor binding domain to facilitate efficient binding to mouse ACE2. §§ **Chimeric mouse-adapted SARS-CoV1 MA15** variant encoding the SARS-CoV2 RNA-dependent RNA polymerase ('SARS1/SARS2-RdRp'). ¶¶ **Genetic ablation** of type I (Ifnar1<sup>-/-</sup>), III interferon (IFN) receptors (I128<sup>-/-</sup>) and Signal transducer and activator of transcription 2 (STAT2<sup>-/-</sup>). □ □ **hACE2**: chimera expressing human ACE2 receptor. \*\*\* **C57BL/6 Mice Ces1c<sup>-/-</sup>**: lack a serum esterase, an enzyme that is not present in humans, that reduces markedly the remdesivir half-life. ††† **WPH**: whole-body plethysmography



**Table 3. Summary of studies using hamsters models of COVID-19**

Species (ref)	Number Age (Gender)	Virus strain Dose* (Inoculation Route)†	Clinical signs	Viral replication‡ (DPI) §	Pathology (DPI)	Immune response	Seroconversion (DPI)	Outcome Measures
<b>Syrian hamsters</b> Chan, J. F. et al (2020) <sup>56</sup>	n=8 6-10 weeks (M/F) (Donor)	SARS-CoV-2 Hong Kong 10 <sup>5</sup> PFU (IN)	Tachypnea Weight loss Lethargy Ruffled furs Hunched back posture	Nose, trachea, lung Intestine (high viral load¶) (2-7)  blood (low viral load)	Diffuse alveolar damage (exudative) Apoptosis Diffuse alveolar damage (proliferative) Tissue repair intestinal villi damage and necrosis Reduced spleen size (2-14)	Upregulation of Interferon-γ and proinflammatory chemokine, cytokine genes expression  early convalescent serum Immunoprophylaxis decreased nasal and lung viral load but not lung pathology or clinical signs	IgG antibody response against SARS-CoV-2 (7)	Viral transmission and immunoprophylaxis
	n=8 6-10 weeks (M/F)	Direct contact with donor Inoculated with 100ul of PBS	Less weight loss than inoculated animals	No difference in viral load inoculated animals vs. infected animals via contact (4)	No difference inoculated vs. infected by contact	NA	IgG antibody response against SARS-CoV-2 (7)	
<b>Syrian hamsters</b> Rogers, T.F. et al (2020) <sup>57</sup>	n=6 (mAb CC12.1 or CC12.23) ¶	SARS-CoV-2 (USAWA1/2020) 1X10 <sup>6</sup> PFU (IN) 12h post-Ab infusion	weight loss dose-dependent	Reduced lung viral load	NA	NA	Neutralizing antibody	Immunoprophylaxis and therapy
	n=6 Control IgG1 (Den3) □	SARS-CoV-2 (USAWA1/2020) 1X10 <sup>6</sup> PFU (IN) 12h post- Ab infusion	Weight loss	No difference in lung viral loads control vs. low dose groups	NA	NA	NA	
<b>Golden Syrian hamsters</b> Sia, S. F. et al (2020) <sup>58</sup>	(n=3) 4-5 weeks (M) (Donor)	SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 0  8 x 10 <sup>4</sup> TCID <sub>50</sub> (IN)	Weight loss (6) ruffled hair coat (5)	upper respiratory tract, Nose, olfactory neurons, bronchus, lung kidney, duodenum	Inflammatory infiltrates nasal turbinate Progressive lung consolidation (5 to 60%) Mononuclear cells infiltration. No extrapulmonary pathology No pathology in intestine, spleen, heart, and brain (2, 5, 7)	CD3 positive T lymphocytes in peribronchial region (5)	IgG antibody response against SARS-CoV-2 (14)	Viral transmission
	(n=9) 4-5 weeks (M) (Contact)	Infection via contact with donor hamster	weight loss (6) Ruffled hair coat day (4)	Detectable infectious viruses (9/9) day 1 post-contact  No difference in viral shedding contact vs. donor	NA	NA	IgG antibody response against SARS-CoV-2 (14)	

	(n=7) Age: NA (F) Wild type	SARS-CoV-2 (BetaCoV/Belgium/GHB 03021/2020) 2 × 10 <sup>5</sup> TCID <sub>50</sub> (P4 virus) or 2 × 10 <sup>6</sup> TCID <sub>50</sub> (P6 virus) (IN)	NA	Lungs, blood, spleen, liver, upper & lower gastrointestinal tract	Multifocal necrotizing bronchiolitis, Leukocyte infiltration Edema (4)	Increased inflammation-related gene expression  No increase in serum levels of IL- 6, IL-10 and IFN- $\gamma$	NA	
Syrian hamster hamster (STAT2 <sup>-/-</sup> and IL28R-a <sup>-/-</sup> strains)	(n=7) 7-12 weeks (F) STAT2 <sup>-/-</sup>	Same as wild type	NA	Greater levels of viral RNA in lung, spleen, liver, blood and upper and lower gastrointestinal tract in STAT2 <sup>-/-</sup> -hamster vs. WT and IL28ra <sup>-/-</sup>	Lung pathology and inflammation decreased in (STAT2 <sup>-/-</sup> ) but not in IL28R-a <sup>-/-</sup> hamsters (2,3,4)	Increased IL-6 and IL-10 expression in lungs  No increase in serum levels of IL- 6, IL-10 and IFN- $\gamma$	NA	Host interferon response to SARS- CoV-2
Boudewijn s, R. et al (2020) <sup>55</sup>	(n=7) 5-7 weeks (F) IL28R-a <sup>-/-</sup>	Same as wild type	NA	Lungs, blood, spleen, liver, upper & lower gastrointestinal tract  No differences in lung viral RNA levels in WT, vs. STAT2 <sup>-/-</sup> vs. IL28R- a <sup>-/-</sup> hamsters	Bronchopneumonia and peribronchiolar inflammation (2,3,4)	High (MMP)-9 levels in lung homogenates compare to WT  Increased IL-6 and IL-10 expression in lungs  No increase in serum levels of IL- 6, IL-10 and IFN- $\gamma$	NA	

\*TCID<sub>50</sub>: Median Tissue Culture Infectious Dose at which 50% of the cells are infected; PFU: plaque-forming unit. † IN: intranasal ‡ **Viral replication**: RNA copies (PCR), and or viral antigen (Immunostaining), viral particles (electron microscopy). § dpi: day post-inoculation. ¶ **mAb CC12.1**: IP SARS-CoV-2-specific human neutralizing Monoclonal Antibodies. □ **IgG1 (Den3)**: 2 mg of a dengue specific human IgG1

**Table 4. Summary of studies using ferrets, cats, and dog models of SARS-CoV-22 infection**

Species (ref)	Number Age (Gender)	Virus strain Dose* (Inoculation Route)†	Clinical signs	Viral replication‡ (DPI) §	Pathology (DPI)	Immune response	Seroconversion (DPI)	Outcome Measures
<b>Ferrets</b> Kim, Y.-I., et al (2020) <sup>59</sup>	n=12 12- 20 months M/F	NMC-nCoV02/Korea 10 <sup>5.5</sup> TCID <sub>50</sub> IN	Increased body temperature Reduced activity occasional coughs	Nose, saliva, urine, and feces  trachea, lung, kidney, serum, and intestine (2)	Acute bronchiolitis Infiltrates of immune cells and debris (4)	NA‡	IgG and serum- neutralizing antibody response against SARS-CoV-2 (12)	
	n=12 12- 20 months M/F	Control	NO	NO	NO	NO	NO	
	n=6 (naïve direct contact)	Direct contact	Increased body temperature	all animals were infected (2)			IgG and serum- neutralizing antibody response against SARS-CoV-2 (12)	Assess viral transmission
	n=6 (naïve indirect contact)	Indirect contacts	No increased body temperature	Nose, feces (2 out of 6 animals) (4)			IgG antibody response against SARS-CoV-2 (12) serum-neutralizing antibody response in 1 out of 6?	
<b>Ferrets</b> Blanco-Melo, D., et al (2020) <sup>60</sup>	n=6 4 months Castrated Male	USA-WA1/2020 5x10 <sup>4</sup> PFU IN	NA	Nose, trachea (3,7)	NA	Reduced interferon type I and III response  Increase proinflammatory chemokines and cytokines response	NA	Host interferon response
<b>Ferrets</b> Richard, M., et al (2020) <sup>61</sup>	n=4 6-months (F) donor	BetaCoV/Munich/BavPat1/2020 6.10 <sup>5</sup> TCID <sub>50</sub> IN	NA	Nose, throat, rectum	NA	NA	IgG antibody response against SARS-CoV-2 (21)	Viral transmission
	n=4 6-months (F) direct contact	6h post inoculation co-housed with donor	NA	Nose, throat, rectum (1)	NA	NA	IgG antibody response against SARS-CoV-2 (21)	
	n=4 6-months (F) indirect contact	1dpi placed in an opposite cage (10 cm) of donor	NA	Nose, throat, rectum (3)	NA	NA	IgG antibody response against SARS-CoV-2 (21)	

<b>Ferrets</b>	n=10 M/F	SARS-CoV-2 /F13/environment/2020/Wuhan  SARS-CoV2/CTan/human/2020/Wuhan] 10 <sup>5</sup> PFU IN	Fever loss of appetite	Nose, throat, and rectum (low titer) (4-8)	Severe lymphoplasmacytic, perivasculitis Vasculitis. Increased type II pneumocytes, macrophages, and neutrophils in the alveolar septa and alveolar lumen. Mild peribronchitis (13)	NA	IgG antibody response against SARS-CoV-2 (13)
	n=8 M/F	SARS-CoV2/CTan/human/2020/Wuhan] 10 <sup>5</sup> PFU IT	NA	Nose, throat (2-8)	NA	NA	NA
	n =10 6 - 9 months M/F Sub adult	SARS-CoV-2 /CTan/human/2020/Wuhan 10 <sup>5</sup> PFU IN	NA	Nose, soft palate, tonsil, trachea, lungs, and small intestines.	NA	NA	IgG antibody response against SARS-CoV-2 (10)
<b>Cats</b>	n =10 70-100 days M/F Juvenile	SARS-CoV-2 /CTan/human/2020/Wuhan 10 <sup>5</sup> PFU IN	One cat died at 13 dpi	Nose, soft palate, tonsil, trachea, lungs, and small intestines.	Extensive nasal, tonsil, tracheal, lung and small intestine epithelial mucosal lesions (3)	NA	IgG antibody response against SARS-CoV-2 (10)
	n =5 3-months beagles	SARS-CoV-2- 2/CTan/human/2020/Wuhan 10 <sup>5</sup> PFU IN,	NA	Rectum (2/5)	NA	NA	IgG antibody response against SARS-CoV-2 (14)
<b>Dogs</b>	n =2 3month Beagles	exposed to donor	NA	No	NA	NA	No

Shi, J., et al  
(2020)<sup>62</sup>

\***TCID<sub>50</sub>**: Median Tissue Culture Infectious Dose at which 50% of the cells are infected; PFU: plaque-forming unit. †IT: intratracheal; IN: intranasal; CJ: intraconjunctival; OC: ocular; IG: intragastric; PO: per oral; IP: intraperitoneal. ‡ **Viral replication**: RNA copies (PCR), viral antigen (Immunostaining), viral particles (electron microscopy). § **dpi**: day post-inoculation.